Stellar Pharmaceuticals Inc. to Present at the Cowen and Company 30th Annual Healthcare Conference

LONDON, ONTARIO--(Marketwire - February 23, 2010) - Stellar Pharmaceuticals Inc. ("Stellar" or "the Company") (OTCBB: SLXCF), a Canadian pharmaceutical developer and marketer of high quality, cost-effective products for select health care markets, today announced today that its President and Chief Executive Officer, Peter Riehl, will present an update on the Company's business, at the Cowen & Company 30th Annual Healthcare Conference, to be held on Monday, March 8, 2010 at 4:45 p.m. ET at the Boston Marriott Copley Place hotel.

Mr. Riehl's presentation will be webcast live and archived for 30 days on the Company's website at http://www.stellarpharma.com.

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology: NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome, an inflammatory disease of the urinary bladder wall. Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

Forward-looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.